title: Intrauterine insemination after ovarian stimulation with clomiphene citrate: predictive potential of inseminating motile count and sperm morphology.
abstract: This retrospective study aimed to evaluate the prognostic value of the inseminating motile count (IMC) and sperm morphology (using strict criteria) on success rates after homologous intrauterine insemination (IUI) combined with clomiphene citrate (CC) stimulation. A total of 373 couples underwent 792 IUI cycles in a predominantly (87.4%) male subfertility group. The overall cycle fecundity (CF) and baby take-home rate (BTH) was 14.6 and 9.9% respectively. The cumulative CF and BTH (per couple) after three cycles were 30.6 and 21.1% respectively. Overall, sperm morphology and IMC were of no prognostic value using receiver operating characteristic (ROC) curve analysis, but after classifying the study population into different subgroups according to IMC, sperm morphology turned out to be a valuable prognostic parameter in subgroup 1, i.e. IMC <1 x 10(6). In this subgroup, no pregnancies were seen when the morphology score was <4% and the mean value of sperm morphology was significantly different in the pregnant (8.3%) versus non-pregnant group (5.0%; P <0.05). The cumulative CF and BTH after three IUI cycles were comparable for all couples with the exception of those cases in which the IMC was <1 x 10(6) with a morphology score of <4% normal forms. We recorded only two twin pregnancies (2.5%) and no moderate or severe ovarian hyperstimulation syndrome. We conclude that in a selected group of patients without CC resistance and normal ovarian response following CC stimulation [maximum of three follicles with a diameter of >16 mm at the time of administration of human chorionic gonadotrophin (HCG)], IUI combined with CC-HCG can be offered as a very safe and non-expensive first-line treatment, at least with an IMC of >1 x 10(6) spermatozoa. In cases with <1 x 10(6) spermatozoa, CC-IUI remains important as a first-choice therapy provided the morphology score is > or =4%.
authors.affiliation: Genk Institute for Fertility Technology, Z.O.L. Campus St Jan, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Ombelet
authors.forename: H
authors.initials: H
authors.lastname: Vandeput
authors.forename: G
authors.initials: G
authors.lastname: Van de Putte
authors.forename: A
authors.initials: A
authors.lastname: Cox
authors.forename: M
authors.initials: M
authors.lastname: Janssen
authors.forename: P
authors.initials: P
authors.lastname: Jacobs
authors.forename: E
authors.initials: E
authors.lastname: Bosmans
authors.forename: O
authors.initials: O
authors.lastname: Steeno
authors.forename: T
authors.initials: T
authors.lastname: Kruger
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D002996:Clomiphene / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007246:Infertility / Q000628:therapy; D007317:Insemination, Artificial, Homologous; D008297:Male; D008875:Middle Aged; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D013076:Sperm Count; D013094:Spermatozoa / Q000166:cytology*
chemical_list: D006063:Chorionic Gonadotropin; D002996:Clomiphene